CN1528471A - Method for preparing tissue engineered porous composite scaffold material - Google Patents
Method for preparing tissue engineered porous composite scaffold material Download PDFInfo
- Publication number
- CN1528471A CN1528471A CNA2003101080081A CN200310108008A CN1528471A CN 1528471 A CN1528471 A CN 1528471A CN A2003101080081 A CNA2003101080081 A CN A2003101080081A CN 200310108008 A CN200310108008 A CN 200310108008A CN 1528471 A CN1528471 A CN 1528471A
- Authority
- CN
- China
- Prior art keywords
- tissue engineering
- support frame
- tricalcium phosphate
- frame material
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title abstract description 12
- 239000002131 composite material Substances 0.000 title abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 33
- 239000001506 calcium phosphate Substances 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 19
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 12
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 12
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 11
- 235000011010 calcium phosphates Nutrition 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 8
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000012456 homogeneous solution Substances 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000005057 refrigeration Methods 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 5
- 239000000919 ceramic Substances 0.000 claims description 5
- 239000004633 polyglycolic acid Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical group COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 229920002415 Pluronic P-123 Polymers 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920001992 poloxamer 407 Polymers 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 2
- 125000006091 1,3-dioxolane group Chemical class 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- -1 dimethyl sulfoxine Chemical compound 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004275 glycolic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 239000000622 polydioxanone Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 239000004068 calcium phosphate ceramic Substances 0.000 abstract description 3
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 238000005191 phase separation Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000010148 water-pollination Effects 0.000 abstract 1
- 239000008187 granular material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000011148 porous material Substances 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical class COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910021432 inorganic complex Inorganic materials 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- CUXQLKLUPGTTKL-UHFFFAOYSA-M microcosmic salt Chemical compound [NH4+].[Na+].OP([O-])([O-])=O CUXQLKLUPGTTKL-UHFFFAOYSA-M 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a tissue engineering multiaperture composite bracket material preparing method, during the course of preparing multihole material by phase separation, compounding with inorganic calcium phosphate ceramic particles and adding in nonionic surface active agent to obtain large-aperture organic -inorganic composite bracket material, the diameter of aperture 20-400mum and the aperture gap rate 90% above. The material has better hydrophily beneficial to adhesion and growth of cell. According to different composite quantity and sorts of diphase particles, its internal degrading speed can be adjusted, increasing the biocompatibility, and has applied value in bone tissue engineering and bone repairing.
Description
Technical field
The present invention relates to the preparation method of a kind of degradable high polymer and the compound porous support materials of inorganic ceramic granule.
Background technology
At present porous support materials that adopt the method for inserting pore creating material to prepare used in tissue engineering more, as solvent cast/particle leaching technology (Chinese patent CN1316464), the general NaCl granule that adopts certain size, behind the forming materials in deionized water flush away NaCl granule obtain porous structure, but this method complex procedures, the NaCl granule can not be removed totally.And thermic induces the method that is separated fairly simple, can obtain the more simple porous material of constituent, but the aperture that the way that is separated obtains is generally less, about 20～30 μ m, can not satisfy the needs of organizational project, regulate the time of alligatoring among the Chinese patent CN1394654, increased the aperture to a certain extent.But list prepares porous material with one or more degradable high polymers some shortcomings are arranged, as too big in acidity aspect the degraded, cause aseptic inflammation, hydrophilic is poor, the cell absorption affinity a little less than, the mechanical strength deficiency, material less stable in vivo etc., Chinese patent CN1272383 is template with collagen, lyophilizing obtains composite powder after original position on the collagen generates calcium phosphate, and composite powder is mixed with polylactic acid, obtains porous support materials by the method that is separated, calcium phosphorus proportioning in the calcium microcosmic salt is fixed, and degradation rate is non-adjustable.
Summary of the invention
The preparation method that the purpose of this invention is to provide the used in tissue engineering porous compound support frame material is to improve the performance of porous compound support frame material.The method for preparing the used in tissue engineering porous compound support frame material of the present invention specifically comprises the steps:
1) with organic solvent and water by volume, organic solvent: water=84～100: 16～0, stir at normal temperatures and be mixed with mixed solvent;
2) add surfactant in above-mentioned mixed solvent, the weight of added surfactant is 10%～50% of the degradable high polymer weight that adds of step 4), is dissolved in the mixed solvent fully;
3) add the ceramic particle of calcium phosphate, the weight of added ceramic particle is 5%～50% of the degradable high polymer weight that adds of step 4), and ultrasonic dispersing becomes suspension;
4) in above-mentioned suspension by weight volume ratio 1%～20%w/v add degradable high polymer, heated and stirred in 50～90 ℃ water-bath is until forming homogeneous solution.
5) step 4) gained solution is placed in the refrigeration machine 1～3 hour, temperature is controlled at-30～15 ℃, carry out lyophilization afterwards, remove and desolvate, promptly obtain the compound used in tissue engineering porous support materials of degradable high polymer/calcium phosphate/surfactant organic-inorganic.
As required,, the above-mentioned material that makes can be soaked in methanol or ethanol 12～24 hours, have the activating agent of hole wall surface with removal in order further to increase the aperture of porous compound support frame material.
Among the present invention, said degradable high polymer can be wherein at least a of the copolymer (PLGA), polycaprolactone (PCL) of polyglycolic acid (PGA), polylactic acid (PLA), hydroxyacetic acid and lactic acid, poly-dioxanone (PDS) or cyclonite carbonic ester (TMC).Said calcium phosphate can be type alpha tricalcium phosphate (bata-tricalcium phosphate of α-TCP) (β-TCP), amorphous calcium phosphate salt (ACP), hydroxyapatite (HA) or the single-phase calcium phosphate of OCP (OCP), and type alpha tricalcium phosphate/bata-tricalcium phosphate (α-TCP/ β-TCP), bata-tricalcium phosphate/hydroxyapatite (β-TCP/HA), type alpha tricalcium phosphate/hydroxyapatite (α-TCP/HA) or bata-tricalcium phosphate/type alpha tricalcium phosphate/hydroxyapatite (wherein at least a of the complex phase calcium phosphate of β-TCP/ α-TCP/HA).Organic solvent can be formic acid, acetic acid, Ethyl formate, N, dinethylformamide, 1,4-dioxane, 1,3-dioxolanes, benzene, benzyl alcohol, oxolane, chloroform, morpholine, dimethyl sulfoxine or methyl phenyl ethers anisole etc.The Polymer Surface activating agent can be the block copolymer of nonionic Pluronic type, comprises Pluronic F127, Pluronic P123, Pluronic L64 etc.
Compared with the prior art the present invention has significant effect:
The inventive method is by in the process of preparation, add non-ionic surface active agent and effectively increased the aperture, obtained the aperture at 20～400 μ m, porosity is at the compound timbering material of macropore organic-inorganic more than 90%, can satisfy cell epimatrix material to pore size, the requirement of porosity.The process that is separated has been adjusted in the adding of non-ionic surface active agent simultaneously, can obtain bigger hole, has enlarged the range of application of phase disengagement method in organizational project.Hydrophilic has preferably been embodied on the timbering material surface of gained, helps adhering to and growing of cell, reduces material to proteic adsorption.Inorganic calcium phosphate ceramic particle and degradable high polymer are compound, increased the biocompatibility of material, help growing into of cell, the calcium phosphate ceramic particle is the multiphase granules of several degradable calcium microcosmic salts simultaneously, degradation rate in vivo is adjustable, can compensate the decline of the pH value that depolymerization causes, help to prevent the generation of aseptic inflammation.Shortcomings such as the introducing of calcium phosphate has delayed the depolymerization time, can improve the bad mechanical property of polymer, and degradation speed is fast, and synosteosis power is weak.
The specific embodiment
Embodiment 1
With 1,4-dioxane and water stir at normal temperatures with 84: 16 volume ratio and are made into mixed solvent 20ml, add Pluronic F127 0.3 gram and are dissolved in the mixed solvent fully.Add α-TCP granule 0.1 gram in this solution, grain diameter is about 100nm, and ultrasonic dispersing becomes suspension, adds the PLA of 1.0 grams then, and heated and stirred in 80 ℃ water-bath is until forming homogeneous solution.This polymer solution was placed in the refrigeration machine 2 hours, and temperature is controlled at-15 ℃, puts into freeze drying box afterwards and carries out lyophilization 3 days, remove and desolvate, can obtain the compound used in tissue engineering porous support materials of organic-inorganic, the aperture is at 50～300 μ m, and porosity is 95%.
Embodiment 2
In 20ml acetic acid, add Pluronic L64 0.5 gram, dissolving fully.Add the β-TCP granule of particle diameter 0.4 gram about 200nm in this solution, ultrasonic dispersing obtained suspension in 10 minutes.The PLGA that adds 2.0 grams in above-mentioned suspension, heated and stirred in 60 ℃ water-bath is until forming homogeneous solution.This polymer solution was placed in the refrigeration machine 3 hours, and temperature is controlled at-20 ℃, puts into freeze drying box afterwards and carries out lyophilization 3 days, remove and desolvate, can obtain the compound used in tissue engineering porous support materials of organic-inorganic, the aperture is at 30～400 μ m, and porosity is 90%.
Embodiment 3
In being the 20ml mixed solution of oxolane/water of 90/10, volume ratio adds Pluronic F1270.1 gram, dissolving fully under the room temperature.Add ACP granule 0.32 gram in this solution, particle diameter is about 150nm, and ultrasonic dispersing obtained suspension in 10 minutes.The PGA that adds 1.6 grams 8% in above-mentioned suspension, heated and stirred in 90 ℃ water-bath is until forming homogeneous solution.This polymer solution was placed in the refrigeration machine 1 hour, and temperature is controlled at-20 ℃, puts into freeze drying box afterwards and carries out lyophilization 3 days, remove and desolvate, can obtain the compound used in tissue engineering porous support materials of organic-inorganic, the aperture is at 20～300 μ m, and porosity is 92%.
Embodiment 4
In being the 20ml mixed solution of formic acid/water of 93/7, volume ratio adds Pluronic P123 0.3 gram, dissolving fully under the room temperature.Add the α-TCP/ β-TCP multiphase granules of 0.3 gram of particle diameter about 100nm then in this solution, ultrasonic dispersing obtained suspension in 10 minutes.The PGA that adds 3.0 grams in above-mentioned suspension, heated and stirred in 70 ℃ water-bath is until forming homogeneous solution.This polymer solution was placed in the refrigeration machine 2 hours, temperature is controlled at-20 ℃, put into freeze drying box afterwards and carried out lyophilization 3 days, remove and desolvate, in ethanol, soak then, cleaned 12 hours, obtain the aperture at 100～400 μ m, porosity is 91% organic-inorganic complex group weaver journey porous support materials.
Claims (6)
1. the preparation method of used in tissue engineering porous compound support frame material is characterized in that comprising the steps:
1) with organic solvent and water by volume, organic solvent: water=84～100: 16～0, stir at normal temperatures and be mixed with mixed solvent;
2) add surfactant in above-mentioned mixed solvent, the weight of added surfactant is 10%～50% of the degradable high polymer weight that adds of step 4), is dissolved in the mixed solvent fully;
3) add the ceramic particle of calcium phosphate, the weight of added ceramic particle is 5%～50% of the degradable high polymer weight that adds of step 4), and ultrasonic dispersing becomes suspension;
4) in above-mentioned suspension by weight volume ratio 1%～20%w/v add degradable high polymer, heated and stirred in 50～90 ℃ water-bath is until forming homogeneous solution.
5) step 4) gained solution is placed in the refrigeration machine 1～3 hour, temperature is controlled at-30～15 ℃, carries out lyophilization afterwards, removes and desolvates, and gets final product.
2. the preparation method of used in tissue engineering porous compound support frame material according to claim 1 is characterized in that the porous compound support frame material that will make soaks, cleaned 12～24 hours in methanol or ethanol.
3. the preparation method of used in tissue engineering porous compound support frame material according to claim 1 is characterized in that said degradable high polymer is wherein at least a of the copolymer, polycaprolactone of polyglycolic acid, polylactic acid, hydroxyacetic acid and lactic acid, poly-dioxanone or cyclonite carbonic ester.
4. the preparation method of used in tissue engineering porous compound support frame material according to claim 1, it is characterized in that said calcium phosphate can be type alpha tricalcium phosphate, bata-tricalcium phosphate, amorphous calcium phosphate salt, hydroxyapatite or the single-phase calcium phosphate of OCP, and wherein at least a of type alpha tricalcium phosphate/bata-tricalcium phosphate, bata-tricalcium phosphate/hydroxyapatite, type alpha tricalcium phosphate/hydroxyapatite or bata-tricalcium phosphate/type alpha tricalcium phosphate/hydroxyapatite complex phase calcium phosphate.
5. the preparation method of used in tissue engineering porous compound support frame material according to claim 1, it is characterized in that said Polymer Surface activating agent is the block copolymer of nonionic Pluronic type, comprise Pluronic F127, Pluronic P123, Pluronic L64.
6. the preparation method of used in tissue engineering porous compound support frame material according to claim 1, it is characterized in that said organic solvent is formic acid, acetic acid, Ethyl formate, N, dinethylformamide, 1,4-dioxane, 1,3-dioxolanes, benzene, benzyl alcohol, oxolane, chloroform, morpholine, dimethyl sulfoxine or phenylate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310108008 CN1238064C (en) | 2003-10-15 | 2003-10-15 | Method for preparing tissue engineered porous composite scaffold material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310108008 CN1238064C (en) | 2003-10-15 | 2003-10-15 | Method for preparing tissue engineered porous composite scaffold material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1528471A true CN1528471A (en) | 2004-09-15 |
| CN1238064C CN1238064C (en) | 2006-01-25 |
Family
ID=34304599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310108008 Expired - Fee Related CN1238064C (en) | 2003-10-15 | 2003-10-15 | Method for preparing tissue engineered porous composite scaffold material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1238064C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101873869A (en) * | 2007-10-26 | 2010-10-27 | 国家免疫学研究所 | Biodegradable polymer support and preparation method thereof |
| CN102935246A (en) * | 2011-08-15 | 2013-02-20 | 国家纳米科学中心 | Three-dimensional cell culture scaffold, its preparation method and application |
| CN102940905A (en) * | 2012-10-19 | 2013-02-27 | 华中科技大学 | Porous bone repair material having antitubercular activity and preparation method thereof |
| CN103691001A (en) * | 2013-12-30 | 2014-04-02 | 西南交通大学 | Method for preparing three-dimensional porous stent composite layer |
| CN106334217A (en) * | 2016-10-19 | 2017-01-18 | 深圳市艾科赛龙科技股份有限公司 | 3D printing PCL/beta-TCP composite material and preparation method, application and printing method thereof |
| CN107126582A (en) * | 2017-06-02 | 2017-09-05 | 北京航空航天大学 | The preparation of amorphous calcium phosphate/PLA electrospun scaffolds |
| CN107823715A (en) * | 2017-10-20 | 2018-03-23 | 昆明理工大学 | A kind of compound porous bone tissue engineering scaffolds of PCL/HA and preparation method thereof |
| CN108210996A (en) * | 2016-12-14 | 2018-06-29 | 三维天工（北京）科技有限公司 | A kind of preparation method of high elastic and strength nanometer hydroxyapatite/polycaprolactone composite material |
| CN113456880A (en) * | 2021-07-31 | 2021-10-01 | 合肥启灏医疗科技有限公司 | Biodegradable material and suturing nail |
-
2003
- 2003-10-15 CN CN 200310108008 patent/CN1238064C/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101873869A (en) * | 2007-10-26 | 2010-10-27 | 国家免疫学研究所 | Biodegradable polymer support and preparation method thereof |
| CN102935246A (en) * | 2011-08-15 | 2013-02-20 | 国家纳米科学中心 | Three-dimensional cell culture scaffold, its preparation method and application |
| CN102940905A (en) * | 2012-10-19 | 2013-02-27 | 华中科技大学 | Porous bone repair material having antitubercular activity and preparation method thereof |
| CN103691001A (en) * | 2013-12-30 | 2014-04-02 | 西南交通大学 | Method for preparing three-dimensional porous stent composite layer |
| CN103691001B (en) * | 2013-12-30 | 2015-06-17 | 西南交通大学 | Method for preparing three-dimensional porous stent composite layer |
| CN106334217A (en) * | 2016-10-19 | 2017-01-18 | 深圳市艾科赛龙科技股份有限公司 | 3D printing PCL/beta-TCP composite material and preparation method, application and printing method thereof |
| CN108210996A (en) * | 2016-12-14 | 2018-06-29 | 三维天工（北京）科技有限公司 | A kind of preparation method of high elastic and strength nanometer hydroxyapatite/polycaprolactone composite material |
| CN107126582A (en) * | 2017-06-02 | 2017-09-05 | 北京航空航天大学 | The preparation of amorphous calcium phosphate/PLA electrospun scaffolds |
| CN107823715A (en) * | 2017-10-20 | 2018-03-23 | 昆明理工大学 | A kind of compound porous bone tissue engineering scaffolds of PCL/HA and preparation method thereof |
| CN113456880A (en) * | 2021-07-31 | 2021-10-01 | 合肥启灏医疗科技有限公司 | Biodegradable material and suturing nail |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1238064C (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hossain et al. | Development of microspheres for biomedical applications: a review | |
| Osathanon et al. | Microporous nanofibrous fibrin-based scaffolds for bone tissue engineering | |
| CN102824657B (en) | Bone restoration material and preparation method thereof | |
| Wang et al. | In vivo degradation of three-dimensional silk fibroin scaffolds | |
| US5948020A (en) | Implantable bioresorbable membrane and method for the preparation thereof | |
| Meng et al. | Effects of adding resorbable chitosan microspheres to calcium phosphate cements for bone regeneration | |
| WO2008096334B1 (en) | A collagen/hydroxyapatite composite scaffold, and process for the production thereof | |
| CN100356989C (en) | Method for preparing organic and inorganic nanometer composite organization engineering stent material by using thermal phase separation | |
| CN101549176B (en) | Release oxygen type porous inorganic/organic composite stent material | |
| CN102397588B (en) | Porous magnesium alloy three-dimensional reinforced absorbable medical compound material and preparation method thereof | |
| CN1238064C (en) | Method for preparing tissue engineered porous composite scaffold material | |
| EP1621216B1 (en) | Bioabsorbable polymeric granular porous bone filling material and production method thereof | |
| EP1588724A2 (en) | Composite material comprising fibrous organic material and fibrous calcium phosphate | |
| CN1939543A (en) | Composite stand materials of polylactic acid base/nano-hydroxy-apatite and its production | |
| CN110538350B (en) | PLLA/ZIF-8 composite bone scaffold and preparation method thereof | |
| CN110540404B (en) | Calcium phosphate bone cement with hollow through structure, preparation method and application thereof | |
| CN107903336B (en) | Creatine phosphate modified chitosan material and preparation method and application thereof | |
| KR100372751B1 (en) | Fabrication Method of Porous Biodegradable Polymer Scaffolds for Tissue Engineering | |
| Cai et al. | MBG scaffolds containing chitosan microspheres for binary delivery of IL-8 and BMP-2 for bone regeneration | |
| CN108159502A (en) | Aurantiin microballoon fibroin albumen/hydroxyapatite compound rest and preparation method thereof | |
| CN112206353B (en) | Chitin whisker liquid crystal elastomer modified polylactic acid composite material and preparation method and application thereof | |
| CN103785059A (en) | Bone repair regeneration material and preparation method thereof | |
| CN1270783C (en) | Degradable nanometer composite material for biological and medical use | |
| CN110613863B (en) | Porous scaffold material for promoting vascularization based on silicon-doped hydroxyapatite and preparation method and application thereof | |
| CN1242818C (en) | Degradable composite support frame and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |